Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21401139 | 0.93 | EPHX2 (0.33) | EPHX2SLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL16480370 | 0.93 | SHBG (0.38) | EPHX2SLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL21671136 | 0.90 | LMNA (0.47) | EPHX2SLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL1627515 | 0.90 | LMNA (0.47) | EPHX2SLC1A3SLC1A2SLC1A1LMNA | |
| SCHEMBL25501313 | 0.87 | ALDH1A1 (0.46) | EPHX2 | |
| SCHEMBL25501323 | 0.87 | TSHR (0.43) | EPHX2 | |
| SCHEMBL19420374 | 0.85 | ALDH1A1 (0.35) | EPHX2PSMB5 | |
| SCHEMBL19766286 | 0.84 | SCN9A (0.32) | EPHX2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13568033 | 0.82 | CYP3A4 (0.34) | CHRM4CHRM5CHRM1CHRM3PSMB5 | |
| SCHEMBL6123989 | 0.82 | PPM1B (0.36) | EPHX2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994538-B2 | Latent acids and their use | BASF SE (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2018-01-11 | — | — | US | disclosed |
| US-8415419-B2 | Hydrophilic coating composition and hydrophilic member using the same | FUJIFILM CORPORATION (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20100243221-A1 | HYDROPHILIC COATING COMPOSITION AND HYDROPHILIC MEMBER USING THE SAME | FUJIFILM CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | LTA, C1S, C9 | EPHX2 512/4885SLC1A3 841/4885SLC1A2 312/4885 |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | EPHX2 851/4885SLC1A3 2074/4885SLC1A2 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.